The subscription period in Biosergen’s rights issue starts today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, SOUTH AFRICA, CANADA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Today, September 15, 2022, the subscription period for Biosergen AB’s (publ) (“Biosergen” or the “Company”) upcoming rights issue of units, which was announced on September 2, 2022 (the “Rights Issue”), begins. The subscription period in the Rights Issue runs from and including September 15, 2022, up to and including September 29, 2022. However, note that nominees may have a deadline for subscription in the Rights Issue that falls before September 29, 2022.

The Rights Issue in summary:

• Subscription period: September 15, 2022 – September 29, 2022.
• Trade in unit rights: September 15, 2022 – September 26, 2022.
• Preferred rights: For every one (1) share held on the record date of September 13, 2022, one (1) unit right was received and seven (7) unit rights entitle to subscription of one (1) unit.
• Unit: One (1) unit contains five (5) newly issued shares and three (3) warrants of series TO2.
• Subscription price: SEK 15 per unit, corresponding to SEK 3 per share. The warrants are received free of charge.
• Issue proceeds: In the event of full subscription in the Rights Issue the Company will receive approximately SEK 60.2 million before issue costs, and in the event of full exercise of the warrants, the Company can receive an additional maximum of approximately SEK 54.2 million before issue costs.
• Underwritten level: The rights issue is underwritten to approximately 70 percent through subscription and underwriting commitments.

Subscription with preferential rights
The shareholders or representatives of shareholders who, on the record date of September 13, 2022, were registered in the share register maintained by Euroclear Sweden AB (“Euroclear”) and on behalf of the Company, directly registered shareholders, receive a pre-printed issue report with attached payment advice from Euroclear. In the event that a different number of unit rights than those stated in the preprinted issue report are used for subscription the special application form, which is available on Mangold's website www.emission.mangold.se/, shall be used as a basis for subscription by cash payment.

Shareholders whose holdings of shares in the Company were nominee-registered with a bank or other nominee on the record date do not receive an issue report or a special application form from Euroclear. Subscription and payment must then instead take place in accordance with instructions from the respective trustee.

Subscription without preferential rights
Notification of subscription without preferential rights by a trustee is made in accordance with instructions from the respective trustee. For subscription through an endowment insurance or an investment savings account, please contact your manager. Registration for subscription without preferential rights in other respects is done by sending a registration form by post or e-mail to Mangold or alternatively by electronic subscription with Bank ID on Mangold's website. Registration form and electronic subscription are available on Mangold's website www.emission.mangold.se/.

Advisors
Mangold Fondkommission AB is the financial advisor to Biosergen in connection with the Rights Issue. Advokatfirman Lindahl KB is the legal advisor to the Company in connection with the Rights Issue.